Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Biotechnology

Healthcare
$1.36 +0.83%

+$0.03 today

Market cap
$133.64M
Beta
1.98
P/E (TTM)
-2.1
EPS (TTM)
-$1.77
52W Low $1.13High $6.95

Volume 1.21M

Average 2.00M

ZNTL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Zentalis Pharmaceuticals, Inc.NASDAQ: ZNTL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2024
100.0%
Year-over-year change
—

Gross Margin vs competitors

How ZNTL compares with its peers on the latest reported figures

ZNTL Competitors Peer median
Gross Margin for ZNTL and competitors
Company Period LTM level YoY 3-year change
STROSutro Biopharma, Inc.LTM Mar 202698.7% +1.4 pp+5.1 pp
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
WHWKWhitehawk Therapeutics IncFY202589.4% +197.4 pp+212.8 pp
MGNXMacroGenics, Inc.LTM Mar 202669.9% +7.9 pp-24.0 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
ZNTLZentalis Pharmaceuticals, Inc.FY2025— ——
IMMXImmix Biopharma, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
ALXOALX Oncology Holdings Inc.FY2025— ——
PLRXPliant Therapeutics, Inc.FY2025— ——
TILInstil Bio, Inc.FY2025— ——
Peer median (excluding ZNTL) 89.4%+1.4 pp+5.1 pp

Competitors are the stored peer set for ZNTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00067.43M0
Cost of Revenue00000
Gross Profit00067.43M0
Gross Margin———100.0%—
Research & Development175.6M172.73M235.16M167.77M107.3M
Selling, General & Admin40.94M54.55M59.4M87.12M37.72M
Operating Expenses216.54M227.29M299.51M258.62M152.81M
Depreciation & Amortization544K1.43M1.39M1.29M739K
EBITDA(207.2M)(233.58M)(247.6M)(186.17M)(144.27M)
EBITDA Margin———-276.1%—
Operating Income(216.54M)(227.29M)(299.51M)(191.19M)(152.81M)
Operating Margin———-283.6%—
Interest Income02.26K000
Interest Expense02.58M000
Other Income / Expenses50.15M(10.3M)6.6M25.5M16.19M
Income Before Tax(166.39M)(237.58M)(292.91M)(165.69M)(136.62M)
Pre-Tax Margin———-245.7%—
Income Tax Expense(297K)(469K)(601K)177K442K
Net Income(158.73M)(236.81M)(292.19M)(165.84M)(137.06M)
Net Margin———-246.0%—
EPS (Basic)(3.72)(4.48)(4.47)(2.33)(1.91)
EPS (Diluted)(3.72)(4.48)(4.47)(2.33)(1.91)
Weighted Avg Shares42.69M52.86M65.41M71.08M71.87M
Weighted Avg Shares (Diluted)42.69M52.86M65.41M71.08M71.87M

Zentalis Pharmaceuticals, Inc.

NASDAQ:ZNTL

Intrinsic Alpha fair value

Locked

Current Price

$1.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.